Business
Results of Fundraising
Results of Fundraising.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF OXFORD BIODYNAMICS PLC IN ANY JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED (\"MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, SUCH INFORMATION WILL NO LONGER CONSTITUTE INSIDE INFORMATION.\n \nOXFORD BIODYNAMICS PLC\nResults of Fundraising\nAppointment of Joint Broker\nOxford, UK - 14 March 2024 - Oxford BioDynamics PLC (AIM: OBD, \"OBD\", the \"Company\" and, together with its subsidiaries, the \"Group\"), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, is pleased to announce that it has successfully raised gross proceeds of £9.9 million pursuant to a placing, conducted via an accelerated bookbuild process (the \"Placing\"), through direct subscriptions (the \"Subscriptions\") and a retail offer via the PrimaryBid Platform (the \"PrimaryBid Offer\") (all together the \"Fundraising\").\nConditionally, in aggregate, 89,228,889 new ordinary shares of 1p (\"Ordinary Shares\") each in the Company will therefore be issued pursuant to the Placing (the \"Placing Shares\") at an issue price of 9 pence per new Ordinary Share (\"Issue Price\"). The Placing comprised both a General Placing and a VCT/EIS Placing. Subscribers have conditionally subscribed for, in aggregate, 15,329,996 new Ordinary Shares (the \"Subscription Shares\") at the Issue Price.\nIn addition, retail investors have subscribed for a tota...